By Michael Turner
LONDON (IFR) - Mylan has hired banks for a euro-denominated multi-tranche debut euro bond, a day after the under-fire drugmaker announced it would launch a generic version of its EpiPen allergy injection at half the price.
The company has mandated Deutsche Bank, Citigroup, ING and JP Morgan to host a series of investor meetings in Europe from September 7-9.
The company has been under pressure from US lawmakers and presidential candidate Hillary Clinton for increasing the price of a two-cartridge EpiPen set from around US$100 in 2008 to US$600 today.
- PHOTOS: New art and old relics at Mickey Mouse's NYC gallery 25 Pictures
- PHOTOS: See Yes on 3 supporters react to historic transgender rights Question 3 win 11 Pictures
- PHOTOS: A look back at Queen performing in the 1970s and 1980s 22 Pictures
- All of these celebrities have had their nudes leaked 35 Pictures
- PHOTOS: A look at Idris Elba's style through the years 20 Pictures
- PHOTOS: Heidi Klum's annual Halloween party and other amazing celebrity costumes 17 Pictures
- These are the spookiest cities per capita in the U.S. 5 Pictures
- Food Network star talks pumpkin carving 1 Pictures
- Who is Alexander Edwards, Amber Rose's new boyfriend? 9 Pictures
- Is Cardi B pregnant again? This tweet has people guessing 6 Pictures
- Natural Museum's best wildlife photos of the year 5 Pictures
"That's outrageous," Clinton said in a statement on her website. "It's just the latest troubling example of a company taking advantage of its consumers."
Mylan bosses have sought to deflect some of the criticism by announcing on Monday the impending release of a generic version of the drug, which will be sold at US$300.[nL3N1BA37U]
The Reg S benchmark transaction will be issued by Mylan NV and guaranteed by Mylan Inc.
While this will be Mylan NV's first foray into the euro bond market, the issuer has US$11.43bn of debt outstanding, almost all in US dollars, according to Thomson Reuters data.
Mylan is rated Baa3 by Moody's and BBB- by S&P and Fitch, all with stable outlooks.
(Reporting by Michael Turner, Editing by Helene Durand, Julian Baker)